Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

China flag China · Delayed Price · Currency is CNY
6.39
-0.31 (-4.63%)
Jul 3, 2026, 3:05 PM CST
Market Cap6.56B -9.2%
Revenue (ttm)591.59M +1.3%
Net Income-479.28M
EPS-0.48
Shares Out 1.03B
PE Ration/a
Forward PEn/a
Dividend0.01 (0.16%)
Ex-Dividend DateJul 4, 2025
Volume78,651,339
Open5.35
Previous Close6.70
Day's Range5.35 - 6.90
52-Week Range4.81 - 9.40
Beta-0.12
Analystsn/a
Price Targetn/a
Earnings DateAug 26, 2026

About Beijing SL Pharmaceutical

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People’s Republic of China and internationally. The company’s finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injection; recombinant human basic fibroblast growth factor for external use recombinant human basic fibroblast growth factor gel; human interleukin-11; arsen... [Read more]

Sector Healthcare
Founded 1994
Employees 901
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002038
Full Company Profile

Financial Performance

In 2025, Beijing SL Pharmaceutical's revenue was 623.64 million, a decrease of -5.57% compared to the previous year's 660.42 million. Losses were -347.20 million, 368.8% more than in 2024.

Financial Statements